Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Is Not For Sale, CEO Says; Plavix Woes Partly Offset By Other Products

Executive Summary

Bristol-Myers Squibb Interim CEO Jim Cornelius is becoming more confident the company can operate as an independent entity going forward

You may also be interested in...



Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist

The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm

Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist

The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm

Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent

Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged

Related Content

UsernamePublicRestriction

Register

PS047723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel